Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 6/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 6/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498227 | 0.80 | NR1H4 (0.47) | GABRB3GABRA2GABRB2NOTUMALDH1A1 | |
| SCHEMBL2771556 | 0.79 | PDE4B (0.39) | NOTUMALDH1A1KCNJ5KCNJ3LMNA | |
| SCHEMBL497822 | 0.77 | GABRB3 (0.51) | GABRB3GABRA2GABRB2NOTUMALDH1A1 | |
| SCHEMBL498171 | 0.76 | NR1H4 (0.44) | GABRB3GABRA2GABRB2NOTUMALDH1A1 | |
| SCHEMBL21834180 | 0.75 | NOTUM (0.62) | NOTUMALDH1A1CYP1A2LMNAHTT | |
| SCHEMBL2772926 | 0.75 | P2RX7 (0.39) | GABRB3GABRA2GABRB2LMNA | |
| SCHEMBL2772721 | 0.74 | KCNJ5 (0.39) | KCNJ5KCNJ3NR1H4MAPK1 | |
| SCHEMBL3769629 | 0.73 | GABRB3 (0.39) | GABRB3GABRA2GABRB2ALDH1A1 | |
| SCHEMBL2772997 | 0.72 | RORC (0.38) | KCNJ5KCNJ3 | |
| SCHEMBL25044741 | 0.71 | ALDH1A1 (0.49) | NOTUMALDH1A1CYP1A2LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GABRB3 448/4885GABRA2 1161/4885GABRB2 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.